Fight CRC Clinical Trial Finder
NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT03155061 |
TitleStudy of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2017-05-16 |
Location
Japan
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
ONO-4538, ONO-4578, Opdivo |
Tags
MSS/ MMRp
|
NCT ID NCT02925234 |
TitleThe Drug Rediscovery Protocol (DRUP Trial) | Phase
Phase 2
|
Date Added 2016-10-05 |
Location
Netherlands
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT04085185 |
TitleA Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors | Phase
Phase 1
|
Date Added 2019-09-11 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
IBI110, IBI110+ Sintilimab, IBI110, Sintilinab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT02617277 |
TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | Phase
Phase 1
|
Date Added 2015-11-30 |
Location
Colorado, United States
Florida, United States Tennessee, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
AZD1775, MEDI4736 |
Tags
MSS/ MMRp
|
NCT ID NCT04550897 |
TitleA Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients | Phase
Phase 1
|
Date Added 2020-09-16 |
Location
Norway
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
BM7PE |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03368963 |
TitleTAS102 in Combination With NAL-IRI in Advanced GI Cancers | Phase
Phase 1, Phase 2
|
Date Added 2017-12-11 |
Location
Georgia, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05291156 |
TitleCAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | Phase
Phase 2
|
Date Added 2022-03-22 |
Location
Italy
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Avelumab, cetuximab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03476681 |
TitleStudy of NEO-201 in Solid Tumors Expansion Cohorts | Phase
Phase 1, Phase 2
|
Date Added 2018-03-26 |
Location
Maryland, United States
Virginia, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
NEO-201 in combination with pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID VAPER |
TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer | Phase
Phase 1
|
Date Added 2015-11-17 |
Location |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Celecoxib, Cyclophosphamide, imiquimod, vaccine |
Tags
MSS/ MMRp
|
NCT ID NCT03502733 |
TitleTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | Phase
Phase 1
|
Date Added 2018-04-19 |
Location
Maryland, United States
Texas, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo |
Tags
MSS/ MMRp
|